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Plasmodium parasites undergo a clinically silent and obligatory developmental phase in the host’s liver cells
before they are able to infect erythrocytes and cause malaria symptoms. To overcome the scarcity of compounds
targeting the liver stage of malaria, we screened a library of 1037 existing drugs for their ability to inhibit
Plasmodium hepatic development. Decoquinate emerged as the strongest inhibitor of Plasmodium liver stages,
both in vitro and in vivo. Furthermore, decoquinate kills the parasite’s replicative blood stages and is active
against developing gametocytes, the forms responsible for transmission. The drug acts by selectively and
specifically inhibiting the parasite’s mitochondrial bc1 complex, with little cross-resistance with the antimalarial
drug atovaquone. Oral administration of a single dose of decoquinate effectively prevents the appearance of
disease, warranting its exploitation as a potent antimalarial compound.
The search for active compounds among drugs origi-
nally developed and clinically tested for the treatment
of other diseases is a particularly advantageous ap-
proach in the case of historically neglected diseases
such as malaria. Although a number of reports have
recently emerged where libraries of existing drugs were
screened in the search for inhibitors of the malaria
parasite Plasmodium falciparum [1–6], these screens
have focused solely on the intraerythrocytic life cycle
of Plasmodium infection, when clinical symptoms
occur. However, the liver stage of Plasmodium in-
fection is an obligatory step in the maturation and
replication of mosquito-delivered parasites toward
generating the erythrocyte-infective forms that cause
malaria symptoms [7]. To target the hepatic stage is
therefore highly desirable in the context of malaria
eradication, not only because its asymptomatic nature
makes it ideally suited for prophylactic intervention [8],
but also because the liver can serve as a reservoir for-
Plasmodium vivax and Plasmodium ovale hypnozoites,
dormant parasite forms that may lead to relapses long
after the initial blood infection has been eliminated [9].
In sharp contrast with drugs that kill blood-stage
parasites, only a very limited number of drugs are
available against liver forms. Among these, primaquine is
the only clinically approved drug known to eliminate
liver forms of Plasmodium, including hypnozoites, and
to kill gametocytes, the sexual forms responsible for
transmission of the parasite’s life cycle inside the mos-
quito vector [10]. Despite primaquine’s potentially lethal
side effects that severely limit its use, except for a study
from the 1980s [11], systematic efforts toward the
identification of novel chemical safe entities efficacious
against Plasmodium liver stages have not been reported
[12]. Here, we describe the first screen targeted at
Plasmodium liver stages and the identification of
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decoquinate, a compound that is shown to inhibit multiple
phases of the parasite’s life cycle. Further investigation revealed
decoquinate’s mode of action and established its potential as
a potent and selective antimalarial compound.
METHODS
Ethics Statement
All procedures involving animal models complied with
European and US regulations.
Cells, Parasites, and Mice
Huh7 cells, a human hepatoma cell line, were cultured as
described in the Supplementary Methods.
Two transgenic parasite lines were used in this study: a green
fluorescent protein (GFP)–expressing Plasmodium berghei line
(parasite line 259cl2) [13], as well as a fusion GFP- and firefly
luciferase–expressing P. berghei line (parasite line 676m1cl1)
(PbGFP-Luccon) [14]. Sporozoites from both lines were freshly
obtained through the disruption of salivary glands of infected
female Anopheles stephensi mosquitoes.
Male C57Bl/6 mice aged 6–8 weeks and weighing 20–24 g
were purchased from Charles River and housed in the
pathogen-free facilities of the Instituto de Medicina Molecular
(Lisbon, Portugal).
Drug Library Screen for Activity Against Malaria Liver Stages
Huh7 cells (1800 cells/well) were seeded in 30 lL of complete
Roswell Park Memorial Institute medium in 384-well col-
lagen I coated plates (Greiner Bio-one) and incubated at 37C
with 5% CO2. Forty-eight hours after seeding, prediluted drugs
(5 lL) were added to wells to achieve a final concentration
of 10 lM. After 1 hour, cells were infected with GFP-expressing
P. berghei sporozoites (2000 sporozoites/well) freshly obtained
through disruption of salivary glands of infected female
A. stephensi mosquitoes. Twenty-four hours after infection,
cells were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) and permeabilized with 0.1% Triton
X-100 in PBS, and cell nuclei were stained with Hoechst-
33324 (Invitrogen).
Luminescence Measurement of In Vitro Plasmodium Infection
Inhibition of liver-stage infection was assessed by measuring
the luminescence intensity of Huh-7 cells infected with a firefly
luciferase–expressing P. berghei line, PbGFP-Luccon, as pre-
viously reported [14].
Fluorescence-Activated Cell Sorting (FACS) Analysis
FACS analysis of cells infected with GFP-expressing parasites
allows differentiation between the effect of a drug on hepa-
tocyte invasion and on intrahepatocyte parasite development.
FACS analysis at 2 and 48 hours after sporozoite addition was
performed to determine the percentage of parasite-containing
cells and parasite-GFP intensity within infected cells. Cell sam-
ples for FACS analysis were processed as previously described [15].
In Vivo Drug-Efficacy Studies
All in vivo protocols were approved by the Animal Care
Committee of the Instituto de Medicina Molecular and were
performed according to the regulations of the European
guidelines 86/609/EEG. Drug suspensions in soybean oil
(200 lL/mouse) or in an equivalent amount of vehicle were
administered orally by gavage. Mice were infected by in-
travenous injection of 1 3 104 firefly luciferase–expressing
P. berghei sporozoites. Alternatively, mice were infected by
exposure to the bite of infected female Anopheles stephensi
mosquitoes. Mosquitoes (20 per mouse) were allowed to feed
for 30 minutes on mice anesthetized by intraperitoneal injection
of 180 lL of mixture consisting of 80 mg/kg of ketamine and
10 mg/kg xylazine dissolved in PBS.
Parasite load in the livers was determined 44–46 hours after
infection by real-time in vivo imaging with the in vivo IVIS
Lumina Imaging System [14]. Infection was allowed to proceed
to the blood stage and was monitored by analysis of Giemsa-
stained blood smears of tail blood collected between days 3
and 15 after infection. A compound was considered effective
in the liver if, by day 15 after infection, no parasite could be
detected in the blood smears.
Drug-Susceptibility Testing Against Asexual and Sexual Stages
of 164/GFP Parasites
The drug-susceptibility assay was conducted as previously de-
scribed [6]. Briefly, highly synchronized, young, ring-stage
parasites in 110 lL complete medium (4% hematocrit) were
plated into 96-well plates (Microtest Tissue Culture Plates,
Becton Dickinson) alongside uninfected red blood cells as
a negative control. Sexual commitment was induced by a drop
in hematocrit 24 hours after seeding the parasites. Serial dilu-
tions of compounds were added at that point or 24 hours
later, after reinvasion of parasites. Corresponding dilutions of
chloroform were tested, as well, to account for solvent-specific
effects. On the day of analysis, cells were stained with Hoechst,
and cytometry data were collected as described in detail else-
where [6]. These data were processed with Quanta software
and were analyzed for half-maximal inhibitory concentrations
(IC50), using GraphPad Prism.
Ubiquinol-Cytochrome bc1 Oxidoreductase Activity
Ubiquinol-cytochrome c oxidoreductase activity was mea-
sured as the antimycin-sensitive decylubiquinol-cytochrome c
oxidoreductase level in isolated mitochondria, as detailed in
the Supplementary Methods.
Growth-Inhibition Assays for Evaluation of bc1 Inhibition
The sensitivity of P. falciparum–infected erythrocytes to various
drugs was determined using a [3H]hypoxanthine incorporation
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method with an inoculum size of 0.5% parasitemia and 2%
hematocrit. Plates were incubated at 37C in 5% CO2, 5% O2,
and 95% N2. After 24 hours of incubation, [
3H]hypoxanthine
was added and plates were incubated for an additional
24 hours. After that period, plates were harvested on a glass
fiber filter, using a TOMTEC Cell harvester 96. Filters were
dried and melted on scintillator sheets, and the incorporated
radioactivity was quantified by use of a Wallac Microbeta
Trilux (Model 1450 LS- Perkin Elmer). The Dd2 cell line
containing yeast dihydroorotate dehydrogenase (DHODH)
Figure 1. Screen of compound library. A, Results of the first screening round of 1037 compounds, highlighting the compounds leading to .90%
decrease in infection. Blocker of lipid transport 1 (BLT-1) and its oxidized version (BLT-ox), previously used in the context of liver-stage Plasmodium
infection [20], were used as positive and negative controls, respectively. B, Thirteen compounds selected after the second screening round. The plots in
A and B depict the effect of the drugs on Huh7 cell proliferation (x-axis) and infection by Plasmodium berghei sporozoites (y-axis), measured 24 h after
parasite addition. Each circle represents a compound. Green, yellow, and blue dots represent the dimethyl sulfoxide, positive control, and negative
control, respectively, as above. The horizontal and vertical red lines indicate 100% infection and 100% confluency, respectively. C, Luminescence-based
measurement of dose-dependent effects of selected compounds. Bars represent infection loads, and the red line represents cell confluency. Error bars
represent SDs from 3 independent measurements. D, Luminescence-based measurements of liver parasite loads in mice following oral administration
of selected compounds. Compounds were administered in the indicated amounts 24 h before, concomitantly with, and 24 h after intravenous injection of
10 000 luciferase-expressing P. berghei sporozoites. Error bars represent SDs (n 5 5). E, Blood-stage patency of infection following oral administration
of the same drugs as in D. Decoquinate is highlighted in red in both D and E.
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and its parental strain were cultured in the absence or presence
of proguanil (1 lM). The ScURA1 gene from Saccharomyces
cerevisiae was amplified from genomic DNA and cloned into
the pLN-14 vector. The P. falciparum Dd2attB strain was
transfected by electroporation, and stable transfectants were
selected with blasticidin. Both the Dd2attB_yeastDHODH
strain and its parental strain, Dd2attB, were used in these
assays. Nonlinear regression analysis was used to fit the
normalized results of the dose-response curves, and IC50
data were determined using the Grafit5 software package
(Grafit program; Erithacus Software, Horley, Surrey, United
Kingdom).
Molecular Modeling Studies
The molecular modeling studies were carried out using the
crystal structure of cytochrome bc1 from S. cerevisiae (PDB
3CX5) [16] as a template for generating the Y279S mutation.
This was achieved using the Mutate Residue functionality
within MOE (CCG MOE), which is an implementation of
the method presented by Bower et al [17]. Mutant side-chain
conformations are determined from a systematic rotamer
search, resulting in acceptable side-chain structures that are
based on the local environment. Docking was performed with
the GOLD 5.01 (Genetic Optimization for Ligand Docking)
package, which searches for the best ligand interaction pose,
using a genetic algorithm. Docked ligands were ranked with
GoldScore [18], which is included in the software, and were
defined by the following components: protein-ligand hy-
drogen bond energy, protein-ligand van der Waals energy,
ligand internal van der Waals energy, and ligand torsional
strain energy. This fitness function has been optimized to
predict the ligand-binding position and conformation of the
ligands. Docking was run with standard settings and 1000 ge-
netic algorithm operations. Atovaquone and decoquinate were
docked into the oxidation site in the targeted cytochrome.
Visualization of best-fit docking poses was performed with
PyMOL after energy-minimization of the binding pocket and
docked ligand with MOE (MMFF94x force field).
RESULTS
Chemical Screen Identifies Decoquinate as a Potent Inhibitor of
Plasmodium Liver Infection
We employed an in vitro infection model combining P. berghei
parasites and the Huh7 human hepatoma cell line [15] to
screen a commercially available library composed of 1037 com-
pounds that have reached clinical stages (eg, clinical trials) in
the United States (Supplementary Table 1) for their activity
against Plasmodium liver stages. The high-throughput screen
was carried out in a 384-well format combined with an au-
tomated microscopy high content readout (Supplementary
Figure 1). The effect of each drug on the course of infection
was assessed with the help of customized image analysis al-
gorithms that allow for automatic quantification of both cell
numbers and amount of intracellular parasites [19, 20]. The
library was screened 3 independent times, using a fixed
concentration of 10 lM of each compound. This process
identified 116 compounds that decreased infection by .50%
relative to the control. It is interesting to note that these
compounds are distributed across a wide range of drug
classes, suggesting a multiplicity of possible targets (Supple-
mentary Figure 2). Among these compounds, the 41 pro-
ducing a reduction in infection .90% were selected to
undergo a second screening pass (Figure 1A and Supple-
mentary Table 1), where their dose-response behavior was
evaluated. On the basis of that response, and after exclusion of
cytotoxic drugs, compounds with previously reported anti-
plasmodial activity, and topical drugs, 13 compounds were
chosen to undergo a final round of in vitro screening (Figure
1A and 1B and Supplementary Table 1). In this assay, Huh7
cells and luciferase-expressing P. berghei parasites were used as
previously described [14]. Each compound was assayed at 3
different concentrations, and their effects on infection load and
cell confluence were evaluated by luminescence and fluores-
cence measurements, respectively. With the exception of
nicotine, for which no dose-response was observed, all of the
drugs led to a dose-dependent reduction in the P. berghei
infection rate among Huh7 cells, albeit within different ranges
of compound concentrations (Figure 1C). These results defined
a final list of 12 compounds with proven in vitro activity against
Plasmodium liver stages, which were selected for in vivo eval-
uation (Supplementary Table 1).
The ability of the selected compounds to inhibit infection in
vivo was evaluated in an established rodent model of malaria.
Mice received 3 treatments with 10 or 30 mg/kg of each com-
pound, administered orally 24 hours before, concomitantly
with, and 24 hours after intravenous injection of 10 000 lucif-
erase-expressing P. berghei sporozoites. Liver parasite burdens
Table 1. Effect of Decoquinate on Liver and Blood Stages of
Plasmodium Infection, as Represented by Its Half-Maximal
Inhibitory Concentration (IC50)
Liver Stages
(IC50)
Blood Stages (IC50)
Compound Asexual Sexual
Decoquinate 2.6 6 0.7 10 6 8 36 6 30
Primaquine 7500 11 000 6 5000 [6] No effect [6]
Artemisinin NA 62 6 14 92 6 31
Atovaquone NA 1.8 6 0.2 [6] Slight reduction [6]
IC50 data are mean nM 6 SD. Published IC50 data given for comparison were
taken from [6].
Abbreviation: NA, not available.
A New Multistage Antimalarial Compound d JID 2012:205 (15 April) d 1281
Figure 2. Inhibition of Plasmodium by decoquinate. A, B, Oral administration of 10 mg/kg of decoquinate at various times relative to intravenous injection
of 10 000 luciferase-expressing Plasmodium berghei sporozoites. Luminescence-based measurement of liver parasite loads are shown in A, and blood-stage
patency of infection is shown in B. The inset depicts the structure of the decoquinate molecule. Results shown are representative from 3 independent
experiments. Error bars represent SDs (n5 5). C, D, Half-maximal inhibitory concentration curves representing the effect of decoquinate on parasite (C ) and
gametocyte (D ) load. Each assay represents at least 3 biological replicates with 2 technical replicates per plate. The graphs show mean values of the
experiments, whereas the error bars represent the standard error of the mean. E, Blood-stage patency of infection in mice following oral administration of
a single dose of decoquinate immediately prior to P. berghei sporozoite delivery by mosquito bite (n 5 5). Abbreviation: C, control.
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were determined by luminescence 44 hours after infection
(Figure 1D), and blood parasitemias were monitored daily
for 15 days (Figure 1E). Most notably, decoquinate consis-
tently emerged from our studies as the most potent inhibitor
of Plasmodium infection in vivo, completely abrogating liver
parasitemia and fully preventing the appearance of parasites
in the blood at 10 mg/kg. Decoquinate’s IC50 against liver
stages in vitro was estimated at 2.6 nM, approximately
3000-fold lower than that of primaquine (Table 1 and Supple-
mentary Figure 3A). Flow cytometry analysis of Huh7 cells
infected with GFP-expressing P. berghei sporozoites further
demonstrated that decoquinate acts by inhibiting Plasmodium’s
intracellular replication, rather than its ability to invade hepatic
cells (Supplementary Figure 3B).
Decoquinate Acts on Asexual and Presexual Plasmodium Blood
Forms
We then investigated the degree of protection conferred by
different decoquinate administration schedules relative to par-
asite inoculation. To this end, the drug was administered
orally to mice at 10 mg/kg, at different times relative to in-
travenous injection of 10 000 luciferase-expressing spor-
ozoites (Figure 2A). Our results showed that administration
of decoquinate in any of these schedules significantly de-
creased parasite liver load, compared with untreated controls
(Figure 2A). Interestingly, liver parasite load decreased to
below detectable levels in mice treated immediately prior
to infection, but they eventually developed blood parasitemia,
although significantly delayed (P 5 .00159), while mice
treated 24 hours after infection remained negative for blood-
stage parasites (Figure 2B). This suggests that decoquinate acts
not only on Plasmodium liver stages but also on the blood
forms of the parasite. To confirm this, the effect of decoquinate
on in vitro cultures of P. falciparum strain 164/GFP blood
stages was evaluated using methods described elsewhere [6]
(Figure 2C and Table 1). Indeed, decoquinate displayed a marked
effect on asexual blood stages of Plasmodium, with an IC50 of
the same order of magnitude of that of artemisinin, an effective
blood schizonticidal antimalarial, and approximately 1000-fold
lower than that of primaquine. Crucially, our data also showed
that decoquinate is active against Plasmodium gametocytes, the
presexual blood forms of the parasite responsible for trans-
mission to the invertebrate host, with an IC50 of 36 nM
(Figure 2D and Table 1).
Finally, we sought to establish the minimal decoquinate
dose that would provide complete protection against infection
transmitted to mice by mosquito bite, the most physiologically
relevant transmission route. A single decoquinate dose of 10,
5, or 1 mg/kg was administered orally prior to sporozoite in-
jection by P. berghei–infected mosquitoes, followed by daily
monitoring of blood parasitemia. Results showed that whereas
1 mg/kg of decoquinate could already confer partial pro-
tection, a single 5 mg/kg dose of the compound completely
prevented the appearance of blood-stage parasites (Figure 2E).
Decoquinate Specifically and Selectively Inhibits Plasmodium
Mitochondrial bc1 Complex
Given the structural similarities with other quinolones known
to inhibit Plasmodium’s cytochrome bc1 complex (ubiquinol:
cythocrome c oxidoreductase or respiratory complex III; bc1;
P. falciparum genes 2655541, 811955) [21], we investigated
whether the mechanism of decoquinate’s antimalarial activity
could be explained by bc1 inhibition. To address this, we
initially assessed decoquinate inhibition of bc1 activity on mi-
tochondria isolated from P. falciparum 3D7A parasites and
human HEK293 cells. We found plasmodial bc1 complex to
be susceptible to decoquinate, with an IC50 of 0.002 lM and
a selectivity index of .5000, when compared with its human
counterpart (Table 2). To confirm the antimalarial mode of
action of decoquinate by inhibition of bc1 complex, we then
carried out a series of growth inhibition experiments (Figure 3).
The mitochondrial electron transport chain (ETC) is critical
for parasite survival, inhibition of the P. falciparum cyto-
chrome bc1 being the mode of action of the antimalarial drug
atovaquone [22] (Figure 3A). ETC is used by Plasmodium as
the only way to regenerate mitochondrial coenzyme Q. This is
the electron receptor used by DHODH, a mitochondrion-
located, membrane-anchored enzyme of the pyrimidine
biosynthetic pathway. DHODH is also essential for survival
because Plasmodium cannot salvage pyrimidines [23] (Figure
3A). Artemisinin, a known potent antimalarial, kills the para-
site by a different mechanism, presumably one involving
hemoglobin digestion [24], and can therefore be used as an
appropriate control for assays to measure the mode of action
of growth inhibition. We showed that P. falciparum growth
was effectively inhibited by decoquinate, atovaquone, a spe-
cific DHODH inhibitor, and artemisinin (Figure 3B–E and
Table 3). These drugs were then assayed on a P. falciparum
strain transfected with cytoplasmic S. cerevisiae DHODH
(ScDHODH), which bypasses the endogenous Plasmodium
counterpart that is required for pyrimidine biosynthesis.
ScDHODH uses fumarate instead of mitochondrial coenzyme
Q as an electron acceptor, and therefore the transgenic strain
Table 2. Sensitivity of Ubiquinol:Cytochrome bc1 Activity to
Decoquinate and Atovaquone on Isolated Mitochondria
Ubiquinol Cytochrome
c Reductase
IC50 (mean lM 6 SD)
Decoquinate Atovaquone
P. falciparum 0.002 6 0.0005 0.0002 6 0.00003
HEK293 .10 0.327 6 0.03
Abbreviation: P. falciparum, Plasmodium falciparum.
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is resistant to both bc1 and DHODH inhibitors [23]. This
Plasmodium strain remained sensitive to artemisinin but was
not killed by decoquinate, atovaquone, or the DHODH
inhibitor, suggesting that the latter 3 compounds block
pyrimidine biosynthesis (Figure 3B–E and Table 3). Finally, to
distinguish bc1 from DHODH inhibition, the assay was
performed in the presence of proguanil, which collapses the
mitochondrial membrane potential when electron transport is
inhibited and renders the ScDHODH-expressing strain sensitive
to ETC inhibitors [23]. Addition of proguanil restored inhibition
Figure 3. Antiplasmodial mode of action of decoquinate. A, Generation of P. falciparum mitochondrial membrane potential by bc1 complex–mediated
and dihydroorotate dehydrogenase (DHODH)–mediated reactions. Plasmodium falciparum (P. f.) DHODH is the key enzyme in the reduction of coenzyme Q
(from Q to QH2). QH2 is reoxidized by the bc1 complex with subsequent electron transfer to cytochrome c, resulting in proton translocation and generation
of electropotential across the inner membrane. Inhibitors of the bc1 complex prevent this mode of electropotential generation, as well as reoxidation of
QH2. In this scenario, pyrimidine synthesis can be secured by Saccharomyces cerevisiae DHODH, which bypasses plasmodial DHODH by using fumarate
as the electron acceptor, while a proguanil-sensitive alternate path can provide the necessary membrane potential. Thus, in the presence of atovaquone
or other electron transport inhibitors, the generation of electropotential becomes hypersensitive to proguanil (adapted from [18]). B–E, P. falciparum in
vitro growth curves and genetic rescue with yeast DHODH. Addition of proguanil restores sensitivity of the P. falciparum line with S. cerevisiae DHODH to
decoquinate and atovaquone but not to a specific DHODH inhibitor. Artemisinin is used as a bc1 complex–independent and DHODH-independent control
for growth inhibition. F, Docking pose of decoquinate for the wild-type bc1 complex. A hydrogen bond with H181 and a carbonyl-carbonyl interaction
with E272 are established between protein and ligand. G, Docking poses of ligands for the mutant cytochrome bc1 model. Decoquinate is represented
in yellow and atovaquone in green. Decoquinate is within hydrogen bond distance of H181 and R283, whereas atovaquone loses the ability to interact
with E272 and H181.
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by decoquinate and atovaquone but not by the DHODH
inhibitor (Figure 3B–E and Table 3). Overall, these results show
that decoquinate’s antimalarial mode of action is the potent,
selective, and specific inhibition of P. falciparum mitochondrial
bc1 complex.
Decoquinate Presents Little Cross-Resistance With Atovaquone
Resistance to atovaquone, presently the only drug in clinical
use that targets bc1, emerged rapidly [25]. This raised the need
for alternative bc1 inhibitors with little cross-resistance with
atovaquone-resistant strains, as is the case of quinolones [21].
The fact that, unlike atovaquone [6], decoquinate shows potent
gametocidal activity indicated that the 2 drugs interact differ-
ently with their bc1 complex target. To further predict whether
decoquinate presents cross-resistance with atovaquone, we car-
ried out a molecular docking study that used S. cerevisiae bc1
complex structure (PDB 3CX5) [16] as a surrogate for the
P. falciparum protein. This approach has been used effectively
to study the binding mode of atovaquone, given the high se-
quence identity at the Qo site of cytochrome b [26]. Decoquinate
presented a similar docking pose to 4(1H)-pyridones in the
wild-type protein [27], which is consistent with its IC50
(Figure 3F). The Y279S mutation (yeast numbering) corre-
sponds to one of the most frequent mutations in P. falciparum
and results in resistance to atovaquone [26]. Molecular-docking
runs on a mutated model generated from 3CX5 showed that
Y279 is critical for atovaquone binding, as mutation to S279
(Figure 3G) leads to loss of interaction with E272 and H181
[27, 28]. Introduction of the Y279S mutation led to inversion in
the docking pose of decoquinate. However, the protein-inhibitor
complex is still stabilized by hydrogen bonds with H181 and
R283 and by hydrophobic interactions with residues from the
binding pocket (Figure 3G). Therefore, decoquinate is expected
to inhibit the Y279S mutant of cytochrome bc1 effectively and is
therefore expected to present little cross-resistance with atova-
quone. This prediction was confirmed in a very recent report
that showed that decoquinate indeed possesses limited cross-
resistance against 5 atovaquone-resistant P. falciparum lines [29].
DISCUSSION
Decoquinate is a cheap and widely available coccidiostat com-
monly used in livestock ranging from poultry to mammals [30]
and has been recently identified in a screen for blood-stage
inhibitors of Plasmodium infection [29]. The data presented
here demonstrate that decoquinate is a potent antimalarial,
with transmission blocking potential due to the marked effect
on various stages of Plasmodium’s life cycle. Its identification
stemmed from the first high-throughput, microscopy-based
screen performed to identify compounds that inhibit the
hepatic stage of plasmodial infection. Besides its ability to
inhibit the development of the parasite’s liver stages, deco-
quinate demonstrated strong activity against Plasmodium
blood forms, including gametocytes, which are latent pre-
sexual parasite forms responsible for the transmission of
Plasmodium to Anopheles mosquitoes. This is in contrast with
atovaquone, which has been shown to present activity against
Plasmodium liver stages [31] but to be only slightly effective
against parasites in the early sexual stage [6]. Importantly,
a previous study has concluded that compounds shown to
be gametocytocidal also possess radical curative effects against
true relapsing malarias [32]. Thus, although the present study
does not provide direct evidence for this, decoquinate’s strong
effect against latent gametocytes suggests that it might be
active against hypnozoites, which are latent parasite forms in
the liver. On the other hand, drugs targeting multiple stages
of Plasmodium’s life cycle may present added advantages in
terms of efficacy. Decoquinate inhibits the bc1 complex, an
important, yet underexploited antimalarial target. The rapid
emergence of resistance to atovaquone led to its combination
with proguanil (Malarone), the cost of which limited its
widespread use in resource-poor, disease-endemic areas and
highlighted the need for cheaper alternatives that can over-
come resistance [21]. Given its little cross-resistance with
atovaquone-resistant strains [29], decoquinate may constitute
one such alternative. In this context, and at a time when novel
drugs against malaria are urgently required, this study paves
the way not only for future screening efforts of a similar nature
but also for further exploitation of decoquinate as part of an
antimalarial strategy.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://www.oxfordjournals.org/our_journals/jid/). Supplementary
materials consist of data provided by the author that are published to
benefit the reader. The posted materials are not copyedited. The contents
Table 3. Growth Inhibition of Parental and Transgenic Plasmodium falciparum Strains in the Absence or Presence of Proguanil
IC50 (mean lM 6 SD)
Parasite Strain Proguanil (1 lM) Decoquinate DHODH Inhibitor Atovaquone Artemisinin
Dd2attB Absent 0.003 6 0.0001 0.046 6 0.006 0.002 6 0.00002 0.004 6 0.0008
Dd2attB Present 0.006 6 0.0004 0.048 6 0.002 0.0004 6 2 3 10 –5 0.004 6 0.0008
Dd2attB_yeastDHODH Absent .2.5 .5 .0.035 0.004 6 0.0008
Dd2attB_yeastDHODH Present 0.011 6 0.001 .5 0.001 6 7.5 3 1025 0.003 6 4 3 1025
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of all supplementary data are the sole responsibility of the authors.
Questions or messages regarding errors should be addressed to the author.
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